1-4 of 4
Joseph H. Butterfield, MD
Close
Sort by
Journal Articles

Patient Reported Symptoms and Tryptase Levels in WHO-Defined Systemic Mastocytosis (SM) Versus Mast Cell Activation Syndrome (MCAS) Versus Neither

Darci Zblewski, CNP, Ramy A. Abdelrahman, MBBCh, Dong Chen, MD PhD, Joseph H. Butterfield, MD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD
Journal: Blood
Blood (2014) 124 (21): 3204.
https://doi.org/10.1182/blood.V124.21.3204.3204
Published: 2014
Journal Articles

TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, Potently Inhibits KITD816V and FIP1L1-PDGFRA in Vitro

Jaya Kittur, MD, Terra L Lasho, MT(ASCP), Joseph H Butterfield, MD, Jolene Shorr, Ayalew Tefferi, MD, Animesh D. Pardanani, MBBS, PhD
Journal: Blood
Blood (2008) 112 (11): 2807.
https://doi.org/10.1182/blood.V112.11.2807.2807
Published: 2008
Journal Articles

Cytoreductive Therapy in Systemic Mastocytosis: Outcome Analysis and Response Prediction in 134 Consecutive Patients.

Ken-Hong Lim, Animesh D. Pardanani, MBBS, PhD, Joseph H Butterfield, MD, Chin Yang Li, MD, Ayalew Tefferi, MD
Journal: Blood
Blood (2008) 112 (11): 1759.
https://doi.org/10.1182/blood.V112.11.1759.1759
Published: 2008
Journal Articles

Low Incidence of FIP1L1-PDGFRA in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.

Animesh D. Pardanani, MD, PhD, Rhett P. Ketterling, MD, Chin-Yang Li, MD, Alexandra P. Wolanskyj, MD, Michelle A. Elliott, MD, John K. Camoriano, MD, Joseph H. Butterfield, MD, Gordon W. Dewald, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2005) 106 (11): 2590.
https://doi.org/10.1182/blood.V106.11.2590.2590
Published: 2005